
Sintesi
FoundationOne®CDx può essere di supporto al medico nella scelta della terapia o per identificare gli studi clinici con farmaci potenzialmente più efficaci e con un possibile miglioramento degli esiti clinici.
cod. IT/NONP/1804/0001(2)
Riferimenti
- FoundationOne®CDx autorizzazione FDA 2017. Disponibile su: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Consultato nell'agosto 2018).
- FoundationOne®CDx autorizzazione FDA 2017. Disponibile su: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587273.htm (Consultato nell'agosto 2018).
- Genomeweb. Foundation Medicine Q3 revenues up 45 percent. Available at: https://www.genomeweb.com/molecular-diagnostics/foundation-medicine-q3-revenues-45-percent [accessed November 2017].
- Schwaederle M et al. Mol Cancer Ther 2015; 14:1488–1494.
- Schwaederle M et al. J Clin Oncol 2015; 33:3817–3825.
- Schwaederle M et al. JAMA Oncol 2016; 2:1452–1459.
- Jardim DL et al. J Natl Cancer Inst 2015; 107:e253.
- National Comprehensive Cancer Network (NCCN) NSCLC guidelines, Version 9, 2017.
- Frampton, G.M. et al. Nat Biotechnol 2013; 31:1023–1031.
- Drilon A et al. Clin Cancer Res 2015; 16:3631–3639.
- Suh JH et al. Oncologist 2016; 21:684–691.
- FoundationOne®Cdx specifiche tecniche. Disponibili su: www.rochefoundationmedicine.com/f1cdxtech.
- Rankin A et al. The Oncologist 2016; 11:1306–1314.
- Ross JS et al. Cancer 2016; 17:2654–2662.
- Hirshfield KM et al. Oncologist 2016; 21:1315–1325.
- Ross JS et al. JAMA Oncol 2015; 1:40–49.
- Reinbolt RE et al. J Clin Oncol 2016; 34 (and supplementary material).
- Rozenblum AB et al. J Thorac Oncol 2017; 2:258–268 (and supplementary material).
- Wheler JJ et al. Cancer Res 2016; 76:3690–3701.
- Schwaederle M et al. Mol Cancer Ther 2016; 15:743–752.
- Yuan Y et al. Oncotarget 2017; 8:26414–26423.
- Dhir M et al. Cancer Med 2017; 1:195–206.
- Rodriguez-Rodriguez L et al. Gynecol Oncol 2016; 141:2–9.